← All Eli Lilly & CO filings

Eli Lilly & CO 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NYSE
LLY
Eli Lilly & CO
10-Q: Eli Lilly's Q2 Revenue Soars 48% on Mounjaro, Zepbound Strength
Eli Lilly and Company reported a significant 48% increase in revenue for the second quarter of 2026, driven by strong performance in its cardiometabolic health products, particularly Mounjaro and Zepbound.
NYSE
LLY
Eli Lilly & CO
10-Q: Eli Lilly Q1 2026 Earnings Surge on Mounjaro & Zepbound
Eli Lilly reports a significant 56% revenue increase in Q1 2026, driven by strong performance of Mounjaro and Zepbound, alongside substantial net income growth.
NYSE
LLY
Eli Lilly & CO
10-Q: Lilly Soars on Blockbuster Drug Sales, Strong Pipeline
Eli Lilly reports exceptional Q3 and YTD 2025 financial results, driven by surging demand for Mounjaro and Zepbound, alongside significant pipeline advancements.
NYSE
LLY
Eli Lilly & CO
10-Q: Eli Lilly Soars on Blockbuster Drug Sales Growth
Eli Lilly reports exceptional Q2 and H1 2025 financial results, driven by surging demand for Mounjaro and Zepbound, alongside significant pipeline advancements.
NYSE
LLY
Eli Lilly & CO
10-Q: Eli Lilly Reports Strong Q1 2025 Revenue Growth Driven by Mounjaro and Zepbound
Eli Lilly's Q1 2025 revenue surged by 45% year-over-year, fueled by strong sales of Mounjaro and Zepbound.
NYSE
LLY
Eli Lilly & CO
10-Q: Eli Lilly Reports Strong Q3 Revenue Growth Driven by Mounjaro and Zepbound, Despite Increased Expenses
Eli Lilly's Q3 2024 results show significant revenue growth driven by Mounjaro and Zepbound, though increased R&D and marketing expenses impacted net income.
NYSE
LLY
Eli Lilly & CO
10-Q: Eli Lilly Reports Strong Q2 2024 Results Driven by Mounjaro and Zepbound Sales
Eli Lilly's Q2 2024 earnings surged, fueled by robust sales of Mounjaro and Zepbound, alongside growth in other key products.
NYSE
LLY
Eli Lilly & CO
10-Q: Eli Lilly Reports Strong Q1 2024 Results Driven by Mounjaro and Zepbound Sales
Eli Lilly's first quarter 2024 results show a significant increase in revenue and net income, primarily driven by strong sales of Mounjaro and Zepbound.